USP14の小分子阻害剤によるプロテアソーム活性増強
Byung-Hoon Lee1, Min Jae Lee, Soyeon Park
1Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, Massachusetts 02115, USA.
Nature
|September 11, 2010
まとめ
USP14はプロテアソーム関連酵素で,タンパク質の分解を抑制する. USP14を阻害すると,プロテアソームの活性が向上し,神経変性疾患に関与する有毒なタンパク質のクリアランスを促進し,酸化ストレスに対する細胞抵抗性を改善します.
科学分野:
- バイオケミストリー バイオケミストリー
- 細胞生物学 細胞生物学
- 神経科学は神経科学である.
背景:
- プロテアソームは,ユビキチン化タンパク質を分解するのに不可欠ですが,その調節は複雑で,完全に理解されていません.
- USP14はプロテアソームに関連したデウビキチン化酵素であり,タンパク質の分解を調節する役割を示唆しています.
- 異常なタンパク質の蓄積は,神経変性疾患とタンパク質毒性ストレスに関連しています.
研究 の 目的:
- プロテアソーム媒介タンパク質分解の調節におけるUSP14の役割を調査する.
- USP14.の小分子阻害剤を特定し,特徴づけること.
- USP14阻害の治療の可能性を評価し,プロテアソーム機能を強化し,プロテオ毒性ストレスを軽減する.
主な方法:
- USP14のデウビキチン化および阻害活性を評価するためのインビトロおよび細胞検査.
- 人間の選択性小分子阻害剤を特定するための高通量スクリーニング USP14.
- プロテアソーム基板の分解と酸化ストレスに対する耐性を分析するために,USP14阻害剤による細胞治療.
主要な成果:
- USP14は,ユビキチン-タンパク質結合体の分解を抑制することが判明しました.
- 触媒的に不活性なUSP14変種は抑制活性が低下し,デウビキチネーションの役割を確認した.
- USP14の選択性小分子阻害剤が特定されました.
- USP14の阻害は,神経変性疾患に関連したプロテアソーム基板の分解を高めました.
- USP14の阻害は酸化タンパク質のクリアランスを加速し,酸化ストレスに対する耐性を高めました.
結論:
- USP14は,プロテアソーム媒介のタンパク質分解の負の調節剤として作用する.
- USP14のデウビキチン活性抑制は,プロテアソーム機能を強化する.
- USP14阻害は,神経変性疾患を含む,タンパク質毒性ストレスと異常なタンパク質蓄積が特徴である状態のための潜在的な治療戦略を表しています.
関連する概念動画
The Proteasome
10.2K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.2K
Eukaryotic Transcription Inhibitors
11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
The Proteasome
4.6K
No description available
4.6K
The Proteasome
1.7K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.7K
The Proteasome Structure
1.7K
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
1.7K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
626
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
626


